Joel Greenblatt United Therapeutics Corp Transaction History

Gotham Asset Management, LLC

$7.56 Billion
Q2 2024

A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in United Therapeutics Corp stock. As of the latest transaction made, Gotham Asset Management, LLC holds 47,593 shares of UTHR stock, worth $17.1 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares

47,593

Previous 46,069 3.31%

Holding current value

$17.1 Million

Previous $10.6 Million 43.26%

% of portfolio

0.2%

Previous 0.16%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$228.26 - $319.04 $347,868 - $486,216	1,524 Added 3.31%	47,593 $15.2 Million
Q1 2024 May 15, 2024	BUY	$210.76 - $249.51 $4.19 Million - $4.96 Million	19,863 Added 75.8%	46,069 $10.6 Million
Q4 2023 Feb 14, 2024	SELL	$214.88 - $256.94 $162,234 - $193,989	-755 Reduced 2.8%	26,206 $5.76 Million
Q3 2023 Nov 14, 2023	SELL	$211.82 - $248.24 $275,366 - $322,712	-1,300 Reduced 4.6%	26,961 $6.09 Million
Q2 2023 Aug 14, 2023	SELL	$205.19 - $232.99 $19,287 - $21,901	-94 Reduced 0.33%	28,261 $6.24 Million
Q1 2023 May 15, 2023	BUY	$212.99 - $276.17 $3.84 Million - $4.98 Million	18,045 Added 175.02%	28,355 $6.35 Million
Q4 2022 Feb 14, 2023	SELL	$205.95 - $280.43 $460,504 - $627,041	-2,236 Reduced 17.82%	10,310 $2.87 Million
Q3 2022 Nov 14, 2022	BUY	$203.3 - $244.17 $705,247 - $847,025	3,469 Added 38.22%	12,546 $2.63 Million
Q2 2022 Aug 15, 2022	BUY	$174.81 - $241.14 $295,079 - $407,044	1,688 Added 22.84%	9,077 $2.14 Million
Q1 2022 May 16, 2022	SELL	$166.16 - $213.96 $278,484 - $358,596	-1,676 Reduced 18.49%	7,389 $1.33 Million
Q4 2021 Feb 14, 2022	SELL	$184.32 - $216.08 $747,233 - $875,988	-4,054 Reduced 30.9%	9,065 $1.96 Million
Q3 2021 Nov 15, 2021	BUY	$179.86 - $214.88 $541,198 - $646,573	3,009 Added 29.76%	13,119 $2.42 Million
Q2 2021 Aug 16, 2021	SELL	$170.47 - $211.93 $1.54 Million - $1.92 Million	-9,054 Reduced 47.24%	10,110 $1.81 Million
Q1 2021 May 17, 2021	BUY	$153.94 - $174.85 $1.16 Million - $1.32 Million	7,546 Added 64.95%	19,164 $3.21 Million
Q4 2020 Feb 16, 2021	SELL	$101.87 - $151.79 $1.75 Million - $2.6 Million	-17,130 Reduced 59.59%	11,618 $1.76 Million
Q3 2020 Nov 16, 2020	SELL	$99.9 - $121.13 $526,473 - $638,355	-5,270 Reduced 15.49%	28,748 $2.9 Million
Q2 2020 Aug 13, 2020	BUY	$92.74 - $125.82 $413,434 - $560,905	4,458 Added 15.08%	34,018 $4.12 Million
Q1 2020 May 15, 2020	SELL	$79.39 - $115.35 $3.15 Million - $4.57 Million	-39,631 Reduced 57.28%	29,560 $2.8 Million
Q4 2019 Feb 14, 2020	BUY	$78.31 - $95.34 $1.69 Million - $2.06 Million	21,574 Added 45.31%	69,191 $6.09 Million
Q3 2019 Nov 14, 2019	SELL	$74.85 - $85.99 $44,610 - $51,250	-596 Reduced 1.24%	47,617 $3.8 Million
Q2 2019 Aug 14, 2019	BUY	$76.06 - $120.81 $2.73 Million - $4.33 Million	35,858 Added 290.23%	48,213 $3.76 Million
Q1 2019 May 15, 2019	SELL	$107.15 - $126.84 $1.99 Million - $2.36 Million	-18,572 Reduced 60.05%	12,355 $1.45 Million
Q4 2018 Feb 14, 2019	SELL	$101.4 - $128.73 $413,813 - $525,347	-4,081 Reduced 11.66%	30,927 $3.37 Million
Q3 2018 Nov 14, 2018	SELL	$113.81 - $129.46 $3.67 Million - $4.17 Million	-32,233 Reduced 47.94%	35,008 $4.48 Million
Q2 2018 Aug 14, 2018	SELL	$101.14 - $118.31 $1.47 Million - $1.72 Million	-14,519 Reduced 17.76%	67,241 $7.61 Million
Q1 2018 May 15, 2018	BUY	$107.21 - $151.94 $1.66 Million - $2.35 Million	15,490 Added 23.37%	81,760 $9.19 Million
Q4 2017 Feb 14, 2018	SELL	$118.58 - $151.28 $13.6 Million - $17.4 Million	-114,915 Reduced 63.42%	66,270 $9.81 Million
Q3 2017 Nov 14, 2017	BUY	$114.6 - $136.81 $20.8 Million - $24.8 Million	181,185	181,185 $21.2 Million

Others Institutions Holding UTHR

# of Institutions

619

Shares Held

45M

Call Options Held

368K

Put Options Held

410K

View Full List

About UNITED THERAPEUTICS Corp

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.3B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

More about UTHR

Track Joel Greenblatt's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.

Account